Related Experiment Video
Updated: Apr 26, 2026
07:44
Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device
Published on: May 2, 2025
1.1K
Survival in granular cell astrocytomas
Benjamin Voellger1, Jorge Humberto Tapia-Perez1, Rosita Rupa1
1Department of Neurosurgery, Otto von Guericke-University, Magdeburg, Germany.
Summary
Adjuvant therapy, including radiotherapy or radiochemotherapy, significantly improves 12-month survival for granular cell astrocytomas (GCAs). Older age (>70) is linked to poorer outcomes in these rare aggressive glial neoplasms.
Area of Science:
- Neuro-oncology
- Neurosurgery
- Radiation Oncology
Background:
- Granular cell astrocytomas (GCAs) are rare, aggressive glial neoplasms with no established standard treatment.
- Treatment modalities include surgery, radiotherapy, and chemotherapy, often tailored due to limited case numbers.
Observation:
- A case of a 64-year-old woman with GCA treated with biopsy and radiochemotherapy using temozolomide is presented.
- Clinical, histopathologic, and MRI data were collected, alongside survival analysis of all reported GCA cases.
Findings:
- Adjuvant therapy (radiotherapy/radiochemotherapy) demonstrated a significant survival benefit at 12 months.
- Age over 70 years at diagnosis was associated with significantly worse 12-month survival.
- No significant impact of extent of resection or gender on survival was observed.
Implications:
- Adjuvant therapy is recommended for patients diagnosed with granular cell astrocytomas to improve survival probability.
- Further research into these rare neoplasms is crucial for developing optimal therapeutic strategies.
